“By fostering greater collaboration between industry, academia, and government, HERC can help bridge the gap between research and commercialization, and support efforts to ensure that Canadians benefit from the latest innovations in life sciences when they need them most,” said IMC President Bettina Hamelin.

IMC remains committed to working alongside the government and its partners as the development and implementation of HERC takes place. Working together will help support the growth of Canada’s life sciences sector and improve the health and wellbeing of Canadians through timely access to the medicines they need.

About Innovative Medicines CanadaInnovative Medicines Canada (IMC) is the national association representing Canada’s innovative pharmaceutical industry. The industry proudly supports over 100,000 high-value jobs, contributes a total of $16 billion to the economy, sponsors the majority of clinical trials in Canada, and invests close to $3 billion in research and development each year. IMC advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians. The association and its members are committed to being solutions-oriented partners in Canada’s healthcare system and have contributed over $30 million towards applied health systems research through the Health Research Foundation (HRF). Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.

Media Relations
Telephone: 613-462-5367
E-mail: media@imc-mnc.ca